Apellis Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
Apellis Pharmaceuticals stock last closed at $20.96, down 3.14% from the previous day, and has decreased 19.38% in one year. It has underperformed other stocks in the Biotechnology industry by 0.02 percentage points. Apellis Pharmaceuticals stock is currently +30.19% from its 52-week low of $16.10, and -31.23% from its 52-week high of $30.48.
There are currently 127.83M APLS shares outstanding. The market cap of APLS is $2.68B. In the last 24 hours, 1.87M APLS shares were traded.
How to Buy Apellis Pharmaceuticals Stock
Wondering how to invest in Apellis Pharmaceuticals stock? Here's how.
Decide where to buy Apellis Pharmaceuticals stock: You need to choose a stock brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you determine where to buy Apellis Pharmaceuticals stock.
Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
Deposit money your investment account: Choose your payment method and add your info.
Analyze Apellis Pharmaceuticals stock: The Apellis Pharmaceuticals ticker symbol is APLS. Is Apellis Pharmaceuticals stock a good investment? Should you buy shares of APLS? How do APLS's underlying business fundamentals look? Do top analysts think Apellis Pharmaceuticals is a good buy? Why has APLS's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if APLS is a good stock to buy).
Execute your APLS trade: Decide if you will purchase APLS shares at the current market price or use a limit order to buy APLS shares at a given price.
Keep tabs on your APLS position: Create a watchlist to keep tabs on your position in Apellis Pharmaceuticals stock.
Step 1: Decide where to buy Apellis Pharmaceuticals stock
You will need a brokerage account to access the NASDAQ market and buy APLS shares.
A brokerage account is an investment account that enables you to buy and sell a variety of financial instruments, such as stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best brokerage. Here's why:
Invest in stocks with 0% commissions: Invest without commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
Access to world markets: From Technology to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by opening an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for a brokerage account
Now that you've picked the right brokerage, the next step is to fill out some personal info so you are able to buy APLS today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Apellis Pharmaceuticals stock
After you have selected the best place to buy Apellis Pharmaceuticals stock, it's absolutely critical to analyze their stock prior to buying, so you actually understand the risk and upside.
Overview of key APLS info
APLS Price
$20.96
1w %
-5.92%
1y %
-19.38%
5y %
-56.04%
P/E
116.44x
P/B
7.24x
P/S
2.63x
PEG
1.79x
Revenue
$1.00B
Earnings
$22.39M
Fore. Rev. Growth
7.89%
Fore. Earn. Growth
65.09%
Market Cap
$2.68B
Next Earnings
Mar 4, 2026
Next Dividend
N/A
Apellis Pharmaceuticals Due Diligence Score
WallStreetZen was created to help average investors perform more in-depth fundamental analysis quickly.
There are more short-term assets than long-term liabilities on the APLS balance sheet.
APLS profit margin has gone up from -25.3% to 2.2% in the past year.
There are more short-term assets than short-term liabilities on the APLS balance sheet.
Total APLS debt is lower than 5 years ago, relative to shareholder equity.
Failed Health Checks:
APLS earnings of $68.44M is not enough to cover its interest payments.
APLS has a relatively high debt to equity ratio of 1.91.
APLS's operating cash flow of $45.33M allows it to safely service it's debt of $474.36M.
Do Wall Street analysts think it's a good time to buy APLS stock
Out of 15 sell side analysts who monitor APLS, the consensus analyst rating on APLS is a Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
Latest APLS Analyst Forecasts
Tazeen Ahmad, a top 27% analyst from Bank of America upgrades APLS to a strong buy rating and maintains their APLS price target from $28.00 to $28.00, on Jan 21, 2026.
Derek Archila, a top 2% analyst from Wells Fargo maintains APLS with a strong buy rating and lowers their APLS price target from $29.00 to $26.00, on Jan 20, 2026.
Steve Seedhouse, a top 38% analyst from Cantor Fitzgerald maintains APLS with a strong buy rating and lowers their APLS price target from $39.00 to $35.00, on Jan 13, 2026.
Joseph Stringer, a top 1% analyst from Needham maintains APLS with a buy rating and lowers their APLS price target from $29.00 to $28.00, on Jan 13, 2026.
Annabel Samimy, a top 7% analyst from Stifel Nicolaus maintains APLS with a strong buy rating and lowers their APLS price target from $55.00 to $48.00, on Dec 19, 2025.
Last year, APLS revenue was $1.00B. Over the past 5 year, APLS's revenue has increased by 31.98% per year. This was slower than the Biotechnology industry average of 32.76%.
Over the past year, insiders at APLS have sold more shares than they have bought.
Mark Jeffrey Delong, Chief Business Strat Officer of APLS, was the latest APLS insider to sell. They sold $8,152.67 worth of APLS shares on Feb 11, 2026.
No, Apellis Pharmaceuticals doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your APLS trade
There are two main options:
Market order: A market order is an order to buy or sell a security at the best available price. Market orders are usually the best for newer investors.
Limit order: A limit order enables you to buy or sell a stock at a specific price (or better). If you want to be certain you're buying or selling at a specific price limit, use a limit order.
Press the Open button and your broker will execute your order.
If you need more assistance buying stocks on eToro, watch the how to video below:
How much does it cost to buy one Apellis Pharmaceuticals share?
As of Feb 27, 2026, it costs $20.96 to buy one share of Apellis Pharmaceuticals stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.477 shares of APLS.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.